List of Excipients in API sacubitril and valsartan
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing sacubitril and valsartan
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | ENTRESTO | sacubitril and valsartan | 0078-0659 | CELLULOSE, MICROCRYSTALLINE | |
| Novartis Pharmaceuticals Corporation | ENTRESTO | sacubitril and valsartan | 0078-0659 | CROSPOVIDONE | |
| Novartis Pharmaceuticals Corporation | ENTRESTO | sacubitril and valsartan | 0078-0659 | FERRIC OXIDE RED | |
| Novartis Pharmaceuticals Corporation | ENTRESTO | sacubitril and valsartan | 0078-0659 | FERROSOFERRIC OXIDE | |
| Novartis Pharmaceuticals Corporation | ENTRESTO | sacubitril and valsartan | 0078-0659 | HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED | |
| Novartis Pharmaceuticals Corporation | ENTRESTO | sacubitril and valsartan | 0078-0659 | HYPROMELLOSES | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing sacubitril and valsartan
Detailed excipient profiles for sacubitril and valsartan
Excipient focus: CELLULOSE, MICROCRYSTALLINE
sacubitril and valsartan drug variants containing CELLULOSE, MICROCRYSTALLINE
sacubitril and valsartan drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
sacubitril and valsartan drug variants containing CROSPOVIDONE
sacubitril and valsartan drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
sacubitril and valsartan drug variants containing FERRIC OXIDE RED
sacubitril and valsartan drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
sacubitril and valsartan drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Aphena Pharma Solutions - Tennessee LLC | sacubitril and valsartan | 71610-806 |
| >Company | >Ingredient | >NDC |
sacubitril and valsartan drug variants not containing FERRIC OXIDE YELLOW
Excipient focus: FERROSOFERRIC OXIDE
sacubitril and valsartan drug variants containing FERROSOFERRIC OXIDE
sacubitril and valsartan drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Aphena Pharma Solutions - Tennessee LLC | sacubitril and valsartan | 71610-806 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
sacubitril and valsartan drug variants containing HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
sacubitril and valsartan drug variants not containing HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
| Company | Ingredient | NDC |
|---|---|---|
| Laurus Labs Limited | sacubitril and valsartan | 42385-930 |
| Alembic Pharmaceuticals Limited | sacubitril and valsartan | 46708-556 |
| Alembic Pharmaceuticals Inc | sacubitril and valsartan | 62332-556 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
sacubitril and valsartan drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Alembic Pharmaceuticals Limited | sacubitril and valsartan | 46708-556 |
| Alembic Pharmaceuticals Inc | sacubitril and valsartan | 62332-556 |
| >Company | >Ingredient | >NDC |
sacubitril and valsartan drug variants not containing HYPROMELLOSE
Excipient focus: HYPROMELLOSE 2910
sacubitril and valsartan drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Laurus Labs Limited | sacubitril and valsartan | 42385-930 |
| >Company | >Ingredient | >NDC |
sacubitril and valsartan drug variants not containing HYPROMELLOSE 2910
Excipient focus: HYPROMELLOSES
sacubitril and valsartan drug variants containing HYPROMELLOSES
sacubitril and valsartan drug variants not containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| Laurus Labs Limited | sacubitril and valsartan | 42385-930 |
| Alembic Pharmaceuticals Limited | sacubitril and valsartan | 46708-556 |
| Alembic Pharmaceuticals Inc | sacubitril and valsartan | 62332-556 |
| >Company | >Ingredient | >NDC |
Excipient focus: LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
sacubitril and valsartan drug variants containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Laurus Labs Limited | sacubitril and valsartan | 42385-930 |
| >Company | >Ingredient | >NDC |
sacubitril and valsartan drug variants not containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
Excipient focus: MAGNESIUM STEARATE
sacubitril and valsartan drug variants containing MAGNESIUM STEARATE
sacubitril and valsartan drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 4000
sacubitril and valsartan drug variants containing POLYETHYLENE GLYCOL 4000
sacubitril and valsartan drug variants not containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
sacubitril and valsartan drug variants containing SILICON DIOXIDE
sacubitril and valsartan drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
sacubitril and valsartan drug variants containing TALC
sacubitril and valsartan drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
sacubitril and valsartan drug variants containing TITANIUM DIOXIDE
sacubitril and valsartan drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
